Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 274-281
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.274
Table 1 Liver disease etiologies among the enrolled patients (n = 478)
Etiologyn (%)
Malignant disease371 (77.6)
HCC323 (67.6)
Colorectal metastasis25 (5.2)
Other metastatic disease12 (2.5)
Cholangiocarcinoma9 (1.9)
Gallbladder carcinoma2 (0.4)
Benign disease107 (22.4)
HCH72 (15.1)
FNH13 (2.7)
Hepatic echinococcosis7 (1.5)
Hepatic complex cysts2 (0.4)
Adenoma9 (1.9)
Cystadenoma3 (0.6)
Table 2 Postoperative complications in the entire patient cohort (n = 478)
Complicationn (%)
Cardiopulmonary90 (18.8)
Myocardial infarction4 (0.8)
Cardiac arrest15 (3.1)
Congestive heart failure6 (1.3)
Respiratory insufficiency/failure112 (2.5)
Pneumonia34 (7.1)
Pleural effusion (symptomatic)19 (4.0)
Liver/biliary70 (14.6)
Increased bilirubin259 (12.3)
Bile leak/biloma5 (1.0)
Cholangitis6 (1.3)
Gastrointestinal12 (2.5)
Ileus5 (1.0)
Gastrointestinal hemorrhage7 (1.5)
Infection34 (7.1)
Deep wound infection23 (4.8)
Sepsis/bacteremia11 (2.3)
Renal and genitourinary59 (12.3)
Renal insufficiency/failure17 (3.6)
Urinary tract infection23 (4.8)
Urinary retention19 (4.0)
Miscellaneous23 (4.8)
Deep venous thrombosis5 (1.0)
Need for reoperation7 (1.5)
Perioperative hemorrhage11 (2.3)
Others310 (2.1)
Table 3 Diagnostic characteristics of total bilirubin, international normalized ratio and combined criteria on postoperative day (3, 5, 7) in the prediction of liver failure-related death
CriteriaAUC95%CISensitivitySpecificityP valueCut-off value
POD 3
TBIL-r10.6860.642-0.72792.90%51.70%0.0181.24
INR-r10.6580.614-0.70164.30%64.90%0.0460.94
Combination10.7190.676-0.75964.30%74.80%0.0050.0337
POD 5
TBIL-r10.9180.890-0.94185.70%87.50%1.0e-71.68
INR-r10.7190.677-0.75950.00%94.80%0.0061.02
Combination10.9510.927-0.96892.90%90.10%9.0e-90.0379
TBIL0.8100.772-0.84478.60%81.50%7.7e-551.0
INR0.7080.665-0.74885.70%64.40%0.0081.23
Combination20.8290.792-0.86199.80%57.50%2.8e-50.0164
POD 7
TBIL-r10.9370.912-0.95785.70%91.60%2.4e-81.61
INR-r10.7960.757-0.83171.40%80.00%1.5e-40.91
Combination10.9750.956-0.98792.90%94.40%1.4e-90.0566
TBIL0.8860.854-0.91392.90%79.10%1.0e-649.5
INR0.7980.760-0.83385.70%73.30%1.4e-41.22
Combination20.9080.879-0.93392.90%79.70%8.7e-70.0277
Table 4 Univariate analysis of factors associated with the hepatic damage score (n = 478)
VariableGroup 1 (n = 380)Group 2 (n = 98)tχ2P value
Age (yr)47.5 ± 12.446.2 ± 11.40.9460.345
Gender0.6390.424
Male30683
Female7215
TBIL (µmol/L)117.5 ± 6.218.6 ± 5.7-1.5160.130
ALB (g/L)140.0 ± 5.039.6 ± 5.00.7370.462
ALT (IU/L)155 ± 4754 ± 300.1170.907
AST (IU/L)160 ± 5464 ± 41-0.5570.578
CREA (µmol/L)10.92 ± 0.280.94 ± 0.27-0.6920.489
ICG R15 (%)17.2 ± 4.38.7 ± 5.5-2.5980.010
INR11.09 ± 0.101.07 ± 0.111.3050.192
HBsAg10.2010.654
Positive26872
Negative11226
CTP grade17.7350.007
A35181
B2917
MELD score15.8 ± 3.86.2 ± 3.4-0.9810.327
IBL (mL)731 ± 790972 ± 953-2.3090.022
IBT (mL)427 ± 764649 ± 943-2.1570.033
RS2.4 ± 1.03.8 ± 1.4-9.8522. 0e-17
Table 5 Multivariate analysis of the hepatic damage score
VariableβSEWaldP valueExp (β)95%CI
LowerUpper
ICG-R150.1760.0335.0803.2e-91.1921.1251.263
RS1.2920.14283.1587.6e-203.6392.7574.803